comprehensive -WSS

comprehensive

author：entertainment 2025-08-12 09:08:40 - browse：2

Adobe

WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American companies, including in the biotech sector. Chinese biotechnology companies, the thinking goes, could threaten national security by giving the Chinese government access to the genetic and health information of Americans.

Just Wednesday, President Biden issued an executive order aimed at keeping sensitive data, including Americans’ genetic information, out of the hands of adversaries.

But American biotech companies worry they could become collateral damage if the government sloppily targets sanctions. They’re pushing back against legislation that would bar biotech companies from working with some Chinese companies, especially as the government takes aim at WuXi, a Chinese company considered a crucial partner for discovering, testing, and making medicines that has worked with such brands as Pfizer, AstraZeneca, and GSK.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： The real point of Kenneth Smith’s execution by nitrogen gas

leisure time

WSS

FDA drug safety: Singulair case shows systemic surveillance flaws

David Sabatini, ex

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Anthos stroke drug appears safer than common blood thinner

FDA drug safety: Singulair case shows systemic surveillance flaws

Hospitals look to new technology to keep health care workers safe

hotspot

comprehensive

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

ChatGPT in medicine: STAT answers readers' burning questions

Quicker fix for pulse oximeters urged during FDA public meeting

Walensky prepares to leave CDC — and Congress — behind

The real point of Kenneth Smith’s execution by nitrogen gas

Heart attack and stroke risk calculators need revising

Even great ERs can’t make up for American health disparities

Duchenne breakthrough therapy leaves behind pioneering families

David Sabatini, ex

hotspot

In key trial, Verve's treatment lowers cholesterol levels in patients

A daunting task: navigating dual Medicare, Medicaid eligibility

General Catalyst, Summa Health deal will turn on physician buy

Do digital therapeutics have a future in medicine?

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

leisure time

focus

entertainment

entertainment